(Q35993244)

English

Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

Per Eystein Lønning

8

object named as

Lonning P

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

Dowsett M

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

MacNeill F

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Mehta A

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Newton C

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Haynes B

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jones A

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jarman M

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Powles TJ

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Coombes RC

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

0 references

publication date

1 November 1991

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

64

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

887-894

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

2 October 2017

Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

2 October 2017

Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

2 October 2017

Compensatory Increase in TSH Secretion without Effect on Prolactin Secretion in Patients Treated with Aminoglutethimide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

2 October 2017

Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

2 October 2017

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

11 July 2018

Single-dose and steady-state pharmacokinetics of aminoglutethimide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

11 July 2018

Analogues of aminoglutethimide: selective inhibition of aromatase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

11 July 2018

Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

11 July 2018

Metabolic clearance rate (MCR) of dehydroepiandrosterone sulfate (DS), its metabolism to dehydroepiandrosterone, androstenedione, testosterone, and dihydrotestosterone, and the effect of increased plasma DS concentration on DS MCR in normal women.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

11 July 2018

Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

11 July 2018

Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977449

23 September 2018

Endocrine Changes Associated with Relapse in Advanced Breast Cancer Patients on Aminoglutethimide Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1931611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biochemical basis for the antagonism between aminoglutethimide and danazol in the endocrine treatment of breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1931611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route

1 reference

https://pubmed.ncbi.nlm.nih.gov/1931611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A

1 reference

https://pubmed.ncbi.nlm.nih.gov/1931611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1931611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A standardised multicentre procedure for plasma gonadotrophin radioimmunoassay

1 reference

https://pubmed.ncbi.nlm.nih.gov/1931611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aminoglutethimide dose and hormone suppression in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1931611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1991.420

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35993244&oldid=2198042073"